RxDoctor Payments Data

Jonathan Masel, MD

Urology · Hollywood, FLNPI 1013900414

Payments from drug & device makers

$9,776in general payments, 2019–2025

Across 314 payments — averaging $31.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$2K
  • Antares Pharma, Inc.$1K
  • Pfizer$773
  • Procept Biorobotics Corporation$476
  • Johnson & Johnson$428
  • Verity Pharmaceuticals Inc.$380
  • plus $4K from 42 others

What the payments were for

  • Travel & lodging$1,24113%
  • Food & beverage$8,35485%
  • Gifts$1802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,776 in reported general payments places this provider in the 70th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$221,351
Medicare patients
528
Services billed
2,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate15$171,096
OrgovyxRelugolix62$164,198
XtandiEnzalutamide11$159,807
MyrbetriqMirabegron61$40,620
GemtesaVibegron20$10,363
Silodosin38$5,198
Tamsulosin Hcl331$3,992
Solifenacin Succinate17$2,878
Testosterone34$2,454
Oxybutynin Chloride ErOxybutynin Chloride92$1,177
Estradiol15$933
Finasteride48$687
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst47$608
Alfuzosin Hcl ErAlfuzosin Hcl31$509
Cefdinir24$467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$209$200,42772 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$28$174,56182 claims
AbbVieLupron Depot$168$171,09615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 urology providers in Florida.

Other urology in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →